RxDoctor Payments Data

Crystal Sipley

Nurse Practitioner · Rome, NYNPI 1912492893

Payments from drug & device makers

$1,130in general payments, 2019–2025

Across 40 payments — averaging $28.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$636
  • Electromed, Inc.$107
  • GSK$83
  • Johnson & Johnson$67
  • Boehringer Ingelheim$43
  • Bayer$42
  • plus $153 from 8 others

What the payments were for

  • Food & beverage$1,130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,130 in reported general payments places this provider in the 85th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$35,806
Medicare patients
264
Services billed
391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate11$145,817
Breztri AerosphereBudesonide/Glycopyr/Formoterol96$87,181
Trelegy ElliptaFluticasone/Umeclidin/Vilanter110$84,388
Spiriva RespimatTiotropium Bromide31$24,518
Breo ElliptaFluticasone/Vilanterol34$21,298
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$10,953
Albuterol Sulfate HfaAlbuterol Sulfate174$6,971
SymbicortBudesonide/Formoterol Fumarate28$6,935
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,930
BreynaBudesonide/Formoterol Fumarate12$2,431
Montelukast Sodium109$1,091
Albuterol Sulfate11$696
Roflumilast11$529
Prednisone40$237
Trazodone Hcl11$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$43$170,33542 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$83$116,639167 claims
AstraZenecaBreztri Aerosphere, Symbicort$636$94,116124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Rome

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →